Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: Studies in FAP mouse models

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Cardoso, Isabel ^a,b   Martins, Diana ^a   Ribeiro, Tania ^a   Merlini, Giampaolo ^c   Saraiva, Maria J ^a,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOXYCYCLINE; GELATINASE B; PREALBUMIN; SERUM AMYLOID P; TAUROURSODEOXYCHOLIC ACID; BIGLYCAN; CHONDROITIN SULFATE; HEAT SHOCK PROTEIN; MOLECULAR CHAPERONE GRP78; PROTEOGLYCAN; SCLEROPROTEIN; TAUROCHENODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; FAMILIAL AMYLOID POLYNEUROPATHY; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROFILAMENT; NONHUMAN; STAINING; ANIMAL; DISEASE MODEL; DRUG ADMINISTRATION; DRUG POTENTIATION; ENZYMOLOGY; METABOLISM; PATHOLOGY; STOMACH; WESTERN BLOTTING;

AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CHONDROITIN SULFATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; EXTRACELLULAR MATRIX PROTEINS; HEAT-SHOCK PROTEINS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; MICE; PREALBUMIN; PROTEOGLYCANS; STOMACH; TAUROCHENODEOXYCHOLIC ACID;

EID: 77954988796     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-74     Document Type: Article

References (29)

1. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007, 36:411-23. 10.1002/mus.20821, 17554795.
2. Araki S, Shigehiro Y, Murakami T, Watanabe S, Ikegawa S, Takahashi K, Yamamura K. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (met30) gene. Mol Neurobiol 1994, 8:15-23. 10.1007/BF02778004, 8086125.
3. Yi S, Takahashi K, Naito M, Tashiro F, Wakasugi S, Maeda S, Shimada K, Yamamura K, Araki S. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am J Pathol 1991, 138:403-12. 1886191, 1992765.
4. Sousa MM, Fernandes R, Palha JA, Taboada A, Vieira P, Saraiva MJ. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin. Am J Pathol 2002, 161:1935-48. 1850789, 12414539.
5. Santos SD, Fernandes R, Saraiva MJ. The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiol Aging 2010, 31:280-9. 10.1016/j.neurobiolaging.2008.04.001, 18485534.
6. Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W, Ross CA, Duan W. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol Dis 2008, 30:293-302. 10.1016/j.nbd.2008.01.014, 2468217, 18395459.
7. Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Kim HS, Park CH, Jeong YH, Yoo J, Lee JP, Chang KA, Kim S, Suh YH. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 2007, 32:2393-404. 10.1038/sj.npp.1301377, 17406652.
8. Riemer C, Burwinkel M, Schwarz A, Gültner S, Mok SW, Heise I, Holtkamp N, Baier M. Evaluation of drugs for treatment of prion infections of the central nervous system. J Gen Virol 2008, 89:594-7. 10.1099/vir.0.83281-0, 18198391.
9. Cardoso I, Merlini G, Saraiva MJ. 4'-iodo-4'-Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing non- cytotoxic species. Screening for TTR fibril disrupters. FASEB J 2003, 17:803-9. 10.1096/fj.02-0764com, 12724338.
10. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 2006, 20:234-39. 10.1096/fj.05-4509com, 16449795.
11. Cardoso I, Brito M, Saraiva MJ. Extracellular Matrix markers in Familial Amyloid Polyneuropathy: disease progression and follow-up of therapies in a transgenic mouse model. Disease Markers 2008, 25:37-47.
12. Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta 2008, 1782:517-22.
13. Puchtler H, Sweat F. Congo Red as a stain for fluorescence microscopy of amyloid. J Histochem Cytochem 1965, 13:693-4.
14. Teixeira PF, Cerca F, Santos SD, Saraiva MJ. Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem 2006, 281:21998-22003. 10.1074/jbc.M602302200, 16751191.
15. Xie Q, Khaoustov VI, Chung CC, Sohn J, Krishnan B, Lewis DE, Yoffe B. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology 2002, 36:592-601. 10.1053/jhep.2002.35441, 12198651.
16. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009, 50:1721-34. 10.1194/jlr.R900011-JLR200, 19417220.
17. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001, 159:1993-2000. 1850610, 11733349.
18. Kelly EA, Jarjour NN. Role of matrix metalloproteinases in asthma. Curr Opin Pulm Med 2003, 9:28-33. 10.1097/00063198-200301000-00005, 12476081.
19. Lee YC, Lee HB, Rhee YK, Song CH. The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma. Clin Exp Allergy 2001, 31:1623-30. 10.1046/j.1365-2222.2001.01211.x, 11678864.
20. Wenzel SE, Balzar S, Cundall M, Chu HW. Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol 2003, 111:1345-52. 10.1067/mai.2003.1464, 12789238.
21. Grimm T, Chovanová Z, Muchová J, Sumegová K, Liptáková A, Duracková Z, Högger P. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm (Lond) 2006, 27:3-1.
22. Slodzinski H, Moran LB, Michael GJ, Wang B, Novoselov S, Cheetham ME, Pearce RK, Graeber MB. Homocysteine-induced endoplasmic reticulum protein (herp) is up-regulated in parkinsonian substantia nigra and present in the core of Lewy bodies. Clin Neuropathol 2009, 28:333-43.
23. Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature 2008, 454:455-62. 10.1038/nature07203, 2727659, 18650916.
24. Heubi JE, Wiechmann DA, Creutzinger V, Setchell KD, Squires R, Couser R, Rhodes P. Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J Pediatr 2002, 141:237-42. 10.1067/mpd.2002.125802, 12183720.
25. Abdul-Hussien H, Hanemaaijer R, Verheijen JH, van Bockel JH, Geelkerken RH, Lindeman JH. Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. J Vasc Surg 2009, 49:741-9. 10.1016/j.jvs.2008.09.055, 19268776.
26. Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T, Lawton MT, Guglielmo BJ, McCulloch CE, Young WL. Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance. Cerebrovasc Dis 2008, 25:157-63. 10.1159/000113733, 2605012, 18212521.
27. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009, 119:2209-16. 10.1161/CIRCULATIONAHA.108.806505, 19364980.
28. Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol 2008, 65:199-204. 10.1001/archneurol.2007.41, 18071030.
29. McCann UD, Ricaurte GA. Caveat emptor: editors beware. Neuropsychopharmacology 2001, 24:333-6. 10.1016/S0893-133X(00)00171-8, 11256359.